Bicara Therapeutics公司公布的数据显示,其1500毫克剂量的Ficerafusp Alfa联合帕博利珠单抗,在一线治疗复发/转移性人乳头瘤病毒阴性头颈鳞状细胞癌患者中,取得了31%的三年总生存率结果。
Bicara Therapeutics公司公布的数据显示,其1500毫克剂量的Ficerafusp Alfa联合帕博利珠单抗,在一线治疗复发/转移性人乳头瘤病毒阴性头颈鳞状细胞癌患者中,取得了31%的三年总生存率结果。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.